KeyCorp Reiterates Buy Rating for Steris Plc (STE) – Dispatch Tribunal


Steris Plc (NYSE:STE)‘s stock had its “buy” rating reissued by analysts at KeyCorp in a research note issued on Tuesday, October 17th. They presently have a $91.00 target price on the medical equipment provider’s stock. KeyCorp’s target price indicates a potential downside of 1.94% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Steris Plc from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research upgraded shares of Steris Plc from a “hold” rating to a “buy” rating and set a $92.00 price objective on the stock in a research note on Tuesday, July 11th. Finally, Raymond James Financial, Inc. raised their price target on shares of Steris Plc from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, October 16th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Steris Plc has an average rating of “Buy” and a consensus target price of $90.75.

Steris Plc (STE) traded up 1.75% during midday trading on Tuesday, reaching $92.80. The company had a trading volume of 386,330 shares. The company’s 50 day moving average is $89.04 and its 200-day moving average is $82.29. Steris Plc has a 52-week low of $63.80 and a 52-week high of $92.96. The company has a market capitalization of $7.91 billion, a P/E ratio of 66.38 and a beta of 1.29.

Steris Plc (NYSE:STE) last announced its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $0.05. The firm had revenue of $608.00 million for the quarter, compared to the consensus estimate of $597.66 million. Steris Plc had a net margin of 4.63% and a return on equity of 11.39%. The business’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.79 earnings per share. Equities analysts expect that Steris Plc will post $4.06 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “KeyCorp Reiterates Buy Rating for Steris Plc (STE)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/29/steris-plc-ste-earns-buy-rating-from-keycorp.html.

In related news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of Steris Plc stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $85.69, for a total transaction of $856,900.00. Following the sale, the chief executive officer now directly owns 83,270 shares in the company, valued at approximately $7,135,406.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Michael J. Tokich sold 11,000 shares of Steris Plc stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $92.00, for a total transaction of $1,012,000.00. Following the sale, the insider now owns 58,588 shares in the company, valued at $5,390,096. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 205,086 shares of company stock worth $17,965,621. 2.55% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Citigroup Inc. bought a new position in Steris Plc during the 2nd quarter worth approximately $206,000. Van Cleef Asset Management Inc bought a new position in Steris Plc during the 2nd quarter worth approximately $208,000. Cigna Investments Inc. New bought a new position in Steris Plc during the 2nd quarter worth approximately $209,000. BT Investment Management Ltd bought a new position in Steris Plc during the 2nd quarter worth approximately $210,000. Finally, Allegis Investment Advisors LLC bought a new position in Steris Plc during the 2nd quarter worth approximately $251,000. Hedge funds and other institutional investors own 94.13% of the company’s stock.

Steris Plc Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Analyst Recommendations for Steris Plc (NYSE:STE)




Receive News & Ratings for Steris Plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Steris Plc and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *